News

MicroAire Completes Acquisition of NEOSYAD

MicroAire Surgical Instruments, the global leader in power-assisted liposuction, is pleased to announce the acquisition of NEOSYAD, an innovative medical device company that developed a breakthrough technology for adipose tissue engineering. This strategic move reinforces MicroAire’s commitment to advancing medical innovation and strengthening its leadership in the adipose tissue market.

NEOSYAD recently received EU MDR approval for their AdiMate® device and Adipure® single-use kit. Thanks to its patented “all-in-one” concept and integrated proprietary software, AdiMate optimizes operating times by combining the infiltration, liposuction, and adipose tissue preparation (lipofilling) functions. The protocol integrated in the machine allows tissue purification in less than 10 minutes in a completely automatic way, while guaranteeing unmatched adipose tissue quality and viability.

Strengthening MicroAire’s Adipose Tissue Leadership

MicroAire’s PAL® handpiece is the #1 power-assisted liposuction device in the United States and a global leader among plastic surgeons. The acquisition of NEOSYAD marks a significant step forward in MicroAire’s vision to strengthen its leadership in the global adipose tissue market. Jerome Barrillon, President of MicroAire, shared his enthusiasm for the partnership: “We are thrilled to welcome the NEOSYAD team into the MicroAire family. Their expertise, innovative products, and dedication to advancing adipose tissue technologies perfectly align with our mission to enable better patient outcomes and support plastic surgeons worldwide.”

Barrillon further emphasized the strategic fit: “NEOSYAD’s advanced adipose tissue technology complements MicroAire’s existing portfolio and will help us accelerate our vision of expanding our leadership in the adipose tissue market. Together, we are poised to deliver unparalleled value to our customers and drive innovation in this growing field.”

Regis Roche, NEOSYAD’s co-founder and President, commented: “We are delighted to join forces with MicroAire, a company that shares our commitment to innovation and excellence in adipose tissue processing. This partnership represents a unique opportunity to scale our groundbreaking solutions and bring the benefits of AdiMate and Adipure to a broader global audience.”

Roche continued: “Our technology has already demonstrated excellent results in enhancing outcomes for patients, particularly in breast reconstruction procedures. By ensuring a higher quality of purified fat and significantly reducing operating times, we enable surgeons to perform procedures with greater precision and efficiency. Together with MicroAire, we aim to make these advanced solutions more accessible to patients worldwide, offering them a safer, more effective option for restoring their confidence and well-being.”

 

Read more here.

Recent News

06/02/2025

Virginia Tech researchers find promise in a new peptide drug to combat a deadly brain cancer

A lab-designed molecule developed and extensively studied by scientists with Virginia Tech’s Fralin Biomedical Research Institute at VTC could represent a breakthrough in slowing tumor recurrence in glioblastoma, an aggressive and deadly form of brain cancer. In a study published May 16 in Cell Death and Disease, researchers identified a previously unknown trait of cancer cells that

05/28/2025

Brandy Salmon named Virginia Tech’s first vice president for innovation and partnerships

Brandy Salmon, who since 2017 has led Virginia Tech teams focused on connecting the university with corporations, foundations, and alumni worldwide has been named the university’s first vice president for innovation and partnerships. “True collaboration between higher education, government, and industry is essential for success in today’s evolving landscape,” said Virginia Tech President Tim Sands.

05/28/2025

Avera Joins Civica to Help Minimize Risk of Drug Shortages

Civica, a nonprofit pharmaceutical company created to prevent and mitigate drug shortages, announced today that Avera, a leading nonprofit healthcare provider in the Upper Midwest United States, has joined the company in helping protect patients from the impact of drug shortages of essential generic sterile injectable medicines. Drug shortages are a persistent challenge to the